Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydantoin SCHEMBL5655843 | 0.86 | GSK3A (0.47) | GSK3AGSK3BMGAMGAASI | |
| Hydantoin SCHEMBL11044399 | 0.84 | GSK3A (0.67) | GSK3AGSK3BMGAMGAASI | |
| Thiazolidinedione SCHEMBL4258537 | 0.80 | GSK3A (0.82) | GSK3AGSK3BMGAMGAASI | |
| Hydantoin SCHEMBL5656545 | 0.79 | CRBN (0.41) | GSK3AGSK3B | |
| Rhodanine SCHEMBL55625 | 0.73 | — | — | |
| Rhodanine SCHEMBL94126 | 0.73 | — | — | |
| Rhodanine SCHEMBL2229918 | 0.73 | GSK3A (1.00) | GSK3AGSK3BMGAMGAASI | |
| Hydantoin SCHEMBL5185641 | 0.72 | GSK3A (0.48) | GSK3AGSK3BMGAMGAASI | |
| Rhodanine SCHEMBL10704409 | 0.71 | — | — | |
| Rhodanine SCHEMBL8017015 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196108-B2 | Bicyclic heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1487446-A4 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1487446-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003075858-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | PC, CYP27A1, GPR119 | GSK3A 1874/4885GSK3B 1952/4885MGAM 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.